Department of Defense Duchenne Muscular Dystrophy Research Program

Research Articles
0
Liestal, Switzerland, August 24, 2011 - Santhera Pharmaceuticals (SIX: SANN) announced today that the United States Patent and Trademark Office granted patent protection for the use of idebenone (brand name Catena®) in the treatment of Duchenne Muscular Dystrophy and other muscular dystrophies. The patent in the United States is supplemented by a similar patent in the European Union granted in 2010.

A Clinical Study to Assess the Efficacy and Safety of GSK2402968 in Subjects With Duchenne Muscular Dystrophy (DMD114044)

Research Articles
0
The purpose of this study is to determine whether GSK2402968 is effective in the treatment of ambulant boys with Duchenne muscular dystrophy resulting from a mutation thought to be corrected by exon 51 skipping.

New compound brings hope of muscular dystrophy remedy

Research Articles
0
A discovery that strengthens the body’s ability to repair muscle tissue could lead to new treatments for people with muscular dystrophy and other degenerative muscle diseases.

Duchenne Muscular Dystrophy Is Ultimately a Stem Cell Disease, Researchers

Research Articles
0
For years, scientists have tried to understand why children with Duchenne muscular dystrophy experience severe muscle wasting and eventual death.

miRNAs as serum biomarkers for Duchenne muscular dystrophy

Research Articles
0
Dystrophin absence in Duchenne muscular dystrophy (DMD) causes severe muscle degeneration. We describe that, as consequence of fibre damage, specific muscle-miRNAs are released into the bloodstream of DMD patients and their levels correlate with the severity of the disease.
1 16 17 18

Monthly Archives

Get Involved

Are you a medical professional or provider? Learn more about how you can help make a difference in the Duchenne community.

CLICK HERE